Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
European Journal of Pediatrics
Erschienen in:

13.10.2022 | Research

Live-attenuated measles, mumps, and rubella booster vaccine in children diagnosed with rheumatic disease: A single-center study

verfasst von: Figen Çakmak, Özlem Akgün, Fatma Gül Demirkan, Ayşe Tanatar, Gülşah Kavrul Kayaalp, Gonca Keskindemirci, Vafa Guliyeva, Rukiye Eker Ömeroğlu, Emine Gülbin Gökçay, Nuray Aktay Ayaz

Erschienen in: European Journal of Pediatrics | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

To evaluate the safety profile of measles, mumps and rubella (MMR) booster in children diagnosed with rheumatic diseases receiving biological agents. The study included retrospective safety data of children administered MMR booster dose receiving biologics or biologics with methotrexate. The files of 182 patients were accessed from the pediatric rheumatology biological therapy archive, and the vaccination status of these children was obtained by accessing electronic records. Of 182 patients, 14 patients were vaccinated with MMR booster dose. Thirteen of the patients were followed up with a diagnosis of juvenile idiopathic arthritis and one with colchicine-resistant familial Mediterranean fever. None of the patients had disease exacerbation after vaccination, and three patients had mild side effects consisting of rash, angioedema, joint pain, and fatigue.
    Conclusion: This study supports the data regarding evidence of the safety of MMR booster dose administration in children with rheumatic diseases receiving bDMARDs.
What is Known:
• MMR booster is avoided in immunocompromised pediatric patients receiving bDMARDs except in specific conditions.
What is New:
• The MMR booster dose may be safe in children with PedRD receiving bDMARDs or bDMARDs with MTX. These bullets can be added to the manuscript.
Literatur
1.
Karadağ ŞG, Sönmez HE, Tanatar A, Çakmak F, Çakan M, Ayaz NA (2020) Profile of new referrals to a single pediatric rheumatology center in Turkey 40(2):313–321
2.
Minden K, Horneff G, Niewerth M, Seipelt E, Aringer M, Aries P, Foeldvari I, Haas JP, Klein A, Tatsis S, Tenbrock K (2019) Time of disease‐modifying antirheumatic drug start in juvenile idiopathic arthritis and the likelihood of a drug‐free remission in young adulthood 71(4):471–481
3.
Baris HE, Anderson E, Sozeri B, Dedeoglu FJCR (2018) Impact of biologics on disease course in systemic onset juvenile idiopathic arthritis 37(12):3263–3273
4.
Becker I, Horneff GJAc (2017) Research: Risk of serious infection in juvenile idiopathic arthritis patients associated with tumor necrosis factor inhibitors and disease activity in the German Biologics in Pediatric Rheumatology Registry 69(4):552–560
5.
Beukelman T, Xie F, Baddley JW, Chen L, Delzell E, Grijalva CG, Mannion ML, Patkar NM, Saag KG, Winthrop KLJA et al (2013) Brief report: incidence of selected opportunistic infections among children with juvenile idiopathic arthritis 65(5):1384–1389
6.
Aygun D, Sahin S, Adrovic A, Barut K, Cokugras H, Camcıoglu Y, Kasapcopur OJCr (2019) The frequency of infections in patients with juvenile idiopathic arthritis on biologic agents: 1-year prospective study 38(4):1025–1030
7.
Giancane G, Swart JF, Tzaribachev N, Rubio N, Cuttica R, Rumba-Rozenfelde I, Suwairi WMS, Lazar C, Uziel Y, Telcharova A (2019) Thu0666 serious/at least moderate infections in patients with juvenile idiopathic arthritis on synthetic and biologic drugs from the Pharmachild registry. BMJ Publishing Group Ltd, InCrossRef
8.
Ada GJNEJoM (2001) Vaccines and vaccination. 345(14):1042–1053
9.
Heijstek M, De Bruin LO, Bijl M, Borrow R, Van Der Klis F, Koné-Paut I, Fasth A, Minden K, Ravelli A, Abinun M (2011) EULAR recommendations for vaccination in paediatric patients with rheumatic diseases 70(10):1704–1712
10.
Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, Van Assen S, Bijl M, Breedveld FC, D'amelio R, Dougados M, Kapetanovic MCJAotrd (2020) 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases 79(1):39–52
11.
Borte S, Liebert U, Borte M, Sack U (2009) Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept 48(2):144–148
12.
Heijstek MW, Pileggi GC, Zonneveld-Huijssoon E, Armbrust W, Hoppenreijs EP, Uiterwaal CS, Kuis W, Wulffraat NM (2007) Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis 66(10):1384–1387
13.
Heijstek MW, Kamphuis S, Armbrust W, Swart J, Gorter S, de Vries LD, Smits GP, van Gageldonk PG, Berbers GA, Wulffraat NMJJ (2013) Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis: a randomized trial 309(23):2449–2456
14.
Bankowski Z, Bruppacher R, Crusius I, Gallagher J, Kremer G, Venulet JJGCfIOoMS (1999) Reporting adverse drug reactions
15.
Bizjak M, Blazina Š, Markelj G, Avčin T, Toplak NJC, Rheumatology E (2019) Vaccination coverage in children with rheumatic diseases 38(1):164–170
16.
Uziel Y, Moshe V, Onozo B, Kulcsár A, Tróbert-Sipos D, Akikusa JD, Pileggi GS, Maritsi D, Kasapcopur O, Rodrigues M (2020) Live attenuated MMR/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: multicenter, retrospective data collection 38(9):2198–2201
17.
Heijstek MW, van Gageldonk PG, Berbers GA, Wulffraat NM (2012) Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study 71(6):948–954
18.
Swart J, Giancane G, Horneff G, Magnusson B, Hofer M, Alexeeva Е, Panaviene V, Bader-Meunier B, Anton J, Nielsen S, De Benedetti F (2018) Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries 20(1):1–11
19.
Miyamoto M, Ono E, Barbosa C, Terreri M, Hilario M, Salomão R, Moraes-Pinto MD (2011) Vaccine antibodies and T-and B-cell interaction in juvenile systemic lupus erythematosus 20(7):736–744
Metadaten
Titel
Live-attenuated measles, mumps, and rubella booster vaccine in children diagnosed with rheumatic disease: A single-center study
verfasst von
Figen Çakmak
Özlem Akgün
Fatma Gül Demirkan
Ayşe Tanatar
Gülşah Kavrul Kayaalp
Gonca Keskindemirci
Vafa Guliyeva
Rukiye Eker Ömeroğlu
Emine Gülbin Gökçay
Nuray Aktay Ayaz
Publikationsdatum
13.10.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Pediatrics / Ausgabe 1/2023
Print ISSN: 0340-6199
Elektronische ISSN: 1432-1076
DOI
https://doi.org/10.1007/s00431-022-04646-x

Weitere Artikel der Ausgabe 1/2023

Point-of-care ultrasound (POCUS) protocol for systematic assessment of the crashing neonate—expert consensus statement of the international crashing neonate working group

  • Open Access
  • Original Article

Is CMV PCR of inner ear fluid during cochlear implantation a way to diagnose CMV-related hearing loss?

  • Research

Evaluation of antibiotic stewardship among near-term and term infants admitted to a neonatal unit

  • Research

Correction to: Comparison of darbepoetin alpha and recombinant human erythropoietin for treatment of anemia in pediatric chronic kidney disease: a non-inferiority trial from India

  • Correction

Infants with macrosomia and infants of diabetic mothers have increased carotid artery intima-media thickness in childhood

  • Research

The burden and surveillance of RSV disease in young children in Belgium—expert opinion

  • Short Communication

Neu im Fachgebiet Pädiatrie

Vorsicht mit Glukokortikoiden bei Glomerulopathie

Auch niedrig dosierte Glukokortikoide zur Behandlung einer primären Glomerulopathie lassen offenbar die Infektionsgefahr steigen. In einer US-Studie hing das Risiko vor allem mit der kombinierten Anwendung von Immunsuppressiva zusammen.

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

Am 15. Januar geht die „ePA für alle“ zunächst in den Modellregionen an den Start. Doch schon bald soll sie in allen Praxen zum Einsatz kommen. Was ist jetzt zu tun? Was müssen Sie wissen? Wir geben in einem FAQ Antworten auf 21 Fragen.

Medikamente verändern wohl Nährstoffzusammensetzung der Muttermilch

Einige Medikamente wie selektive Serotonin-Wiederaufnahmehemmer können offenbar die Makronährstoffzusammensetzung der Muttermilch verändern. Das birgt möglicherweise gesundheitliche Risiken für manche gestillte Kinder.

Kann man Gestationsdiabetes mit oralen Antidiabetika behandeln?

Der Wunsch, Frauen mit Gestationsdiabetes eine orale Erstlinientherapie anbieten zu können, bleibt auch vorläufig ein Wunsch: Eine orale Stufentherapie hat sich in einer randomisierten Studie nicht als gleichwertig zu einer Insulintherapie erwiesen. 

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise